Literature DB >> 8154018

Topical treatment of American cutaneous leishmaniasis with paramomycin and methylbenzethonium chloride: a clinical study under field conditions in Ecuador.

G Krause1, A Kroeger.   

Abstract

Fifty-two patients with American cutaneous leishmaniasis (ACL) from the Pacific coast of Ecuador were treated topically with an ointment containing 15% paramomycin (PR) and 12% methylbenzethonium chloride (MBCL) in vaselinum album (white soft paraffin; white petrolatum). After 20 applications (over 10 or 20 d) all lesions showed complete epithelialization within the first 100 d. Five patients developed new lesions during the one year observation period; 2 of these were probably reinfections. Considering all 5 cases as treatment failures, the healing rates were: 72% after 50 d, 90% after 100 d, and 85% after 360 d. In a separate study in the same area, a group of 23 patients was left without treatment for 3 months. Only 9% of the untreated patients healed spontaneously after 50 d. Growth of the lesion, inflammation and pain were observed at the beginning of treatment. After treatment, most lesions healed rapidly without scars. The drug was well accepted by the patients and was easy to administer under tropical field conditions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8154018     DOI: 10.1016/0035-9203(94)90517-7

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  15 in total

Review 1.  [Therapy of tropical diseases after returning from travel].

Authors:  G D Burchard; H Sudeck
Journal:  Internist (Berl)       Date:  2003-05       Impact factor: 0.743

Review 2.  Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.

Authors:  Begoña Monge-Maillo; Rogelio López-Vélez
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

3.  Cutaneous leishmaniasis in travellers: a focus on epidemiology and treatment in 2015.

Authors:  Adrienne J Showler; Andrea K Boggild
Journal:  Curr Infect Dis Rep       Date:  2015-07       Impact factor: 3.725

Review 4.  An update on pharmacotherapy for leishmaniasis.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  Expert Opin Pharmacother       Date:  2014-10-25       Impact factor: 3.889

5.  Treatment strategies for mucocutaneous leishmaniasis.

Authors:  Emilio Palumbo
Journal:  J Glob Infect Dis       Date:  2010-05

6.  Drug resistance in leishmaniasis.

Authors:  Jaya Chakravarty; Shyam Sundar
Journal:  J Glob Infect Dis       Date:  2010-05

7.  Optimization of topical therapy for Leishmania major localized cutaneous leishmaniasis using a reliable C57BL/6 Model.

Authors:  Hervé Lecoeur; Pierre Buffet; Gloria Morizot; Sophie Goyard; Ghislaine Guigon; Geneviève Milon; Thierry Lang
Journal:  PLoS Negl Trop Dis       Date:  2007-11-28

8.  Efficacy of thermotherapy to treat cutaneous leishmaniasis: a meta-analysis of controlled clinical trials.

Authors:  Jaiberth Antonio Cardona-Arias; Iván Darío Vélez; Liliana López-Carvajal
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

9.  Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials.

Authors:  Dae Hyun Kim; Hye Jin Chung; Joachim Bleys; Reza F Ghohestani
Journal:  PLoS Negl Trop Dis       Date:  2009-02-17

10.  WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study.

Authors:  Afif Ben Salah; Pierre A Buffet; Gloria Morizot; Nathalie Ben Massoud; Amor Zâatour; Nissaf Ben Alaya; Nabil Bel Haj Hamida; Zaher El Ahmadi; Matthew T Downs; Philip L Smith; Koussay Dellagi; Max Grögl
Journal:  PLoS Negl Trop Dis       Date:  2009-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.